scholarly journals Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: Findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS)

2008 ◽  
Vol 2 (1) ◽  
Author(s):  
Peter M Wehmeier ◽  
Alexander Schacht ◽  
Martin Lehmann ◽  
Ralf W Dittmann ◽  
Susan G Silva ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Adverse Event ◽  
Children And Adolescents ◽  
Attention Deficit ◽  
Rating Scale ◽  
Well Being ◽  
Hyperactivity Disorder ◽  
Physician Perspective

Prevalence of Attention Deficit Hyperactivity Disorder Among Pupils in Primary Schools in Ghana

2018 ◽  
Vol 23 (2) ◽  
pp. 69-78
Author(s):  
Daniel Ntiakoh-Ayipah ◽  
Joslin Alexei Dogbe ◽  
Maxwell Peprah Opoku ◽  
Frank Twum ◽  
Michael Owusu ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Students With Disabilities ◽  
Attention Deficit ◽  
Primary Schools ◽  
Rating Scale ◽  
Well Being ◽  
Persons With Disabilities ◽  
Hyperactivity Disorder ◽  
Regular Classrooms ◽  
Teachers And Parents

Abstract In recent times, international deliberations have centered on inaccessibility of essential services to persons with disabilities. These systematic discriminations have accounted for high rates of poverty and deplorable living standards among persons with disabilities. Deliberate attempts are being made to safeguard the rights and well-being of persons with disabilities. In Ghana, one major development is the implementation of inclusive education, to open regular classrooms to children with disabilities. While much is known about the challenges faced by teachers, in terms of lacking skills, facilities and resources to teach students with disabilities in regular classrooms, little attention has been given to their ability to identify students with disabilities. This case study explored the prevalence, common sub-types and distribution of Attention Deficit Hyperactivity Disorder (ADHD) among pupils in primary schools in Ghana. The school and home version of the ADHD Rating Scale IV were used to rate 374 pupils by their teachers and parents. Cluster sampling was used to select 15 schools from a district to take part in this study. The estimated prevalence of ADHD was 7% and more boys were identified with ADHD than girls. With regards to teachers' ratings, most of the pupils fell under inattentive sub-type while hyperactive was the most common sub-type identified by parents. Both teachers and parents identified twenty-one pupils. The need for stakeholders' engagement on public education on ADHD its symptoms and management, have been discussed extensively.

Aripiprazole in Juvenile Bipolar Disorder Comorbid with Attention-Deficit/Hyperactivity Disorder: An Open Clinical Trial

CNS Spectrums ◽  
2007 ◽  
Vol 12 (10) ◽  
pp. 758-762 ◽  
Author(s):  
Silzá Tramontina ◽  
Cristian Patrick Zeni ◽  
Gabriel Ferreira Pheula ◽  
Carla Ketzer de Souza ◽  
Luis Augusto Rohde
Keyword(s):  
Bipolar Disorder ◽  
Attention Deficit Hyperactivity Disorder ◽  
Children And Adolescents ◽  
Attention Deficit ◽  
Rating Scale ◽  
Response To Treatment ◽  
Adhd Symptoms ◽  
Young Mania ◽  
Global Functioning ◽  
Hyperactivity Disorder

ABSTRACTIntroductionJuvenile bipolar disorder (JBD) is a highly impairing chronic mental health condition that affects children and adolescents' overall functioning. Comorbidity with attention-deficit/hyperactivity disorder (ADHD) is extremely prevalent and may determine worse response to treatment. Few investigations have addressed the use of recent atypical antipsychotics in JBD, although several guidelines suggest their use.MethodsWe conducted a 6-week open trial with aripiprazole in 10 children and adolescents with JBD comorbid with ADHD to assess impact on mania and ADHD symptoms, respectively, by means of the Young Mania Rating Scale and the Swanson, Nolan and Pelham Scale, as well as on global functioning (Clinical Global Impressions–Severity), and adverse events.ResultsSignificant improvement in global functioning scores (F=3.17, P=.01, effect size=0.55), manic symptoms (F=5.63, P<.01; ES=0.93), and ADHD symptoms (t=3.42, P<.01; ES=1.05) were detected. Although an overall positive tolerability was reported, significant weight gain (F=3.07, P=.05) was observed.ConclusionAripiprazole was effective in improving mania and ADHD symptoms, but neither JBD nor ADHD symptom remission was observed in most of the cases. Randomized placebo-controlled trials for JBD and ADHD are needed.

scholarly journals Age-Related Changes in Auditory Nogo-N200 Latency in Medication-Naïve Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

2020 ◽  
Vol 17 (7) ◽  
pp. 702-709
Author(s):  
Yeon Jung Lee ◽  
Mi Young Jeong ◽  
Seoyoung Park ◽  
Jung Ho Kim ◽  
Ji-Sun Kim ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Children And Adolescents ◽  
Attention Deficit ◽  
Child Behavior Checklist ◽  
Rating Scale ◽  
Event Related Potential ◽  
Healthy Children ◽  
Hyperactivity Disorder ◽  
Age Related ◽  
Age Related Changes

Objective Event-related potential (ERP) changes with brain development in healthy children and adolescents. However, few studies have focused on age-related changes in the N200 and P300 components among individuals with attention-deficit/hyperactivity disorder (ADHD). Therefore, this study aimed to assess age-related differences in the auditory nogo-N200 components in individuals with ADHD.Methods We enrolled 46 participants with auditory nogo-N200 and nogo-P300 components. We assessed ADHD symptoms using the Advanced Test of Attention (ATA) and Korean ADHD Rating Scale-IV (K-ARS-IV). Moreover, we assessed emotional and behavioral problems using the Korean Child Behavior Checklist (K-CBCL). Further, we measured auditory ERPs.Results There were no differences with respect to sex or ATA, K-ARS-IV, and K-CBCL scores between the groups. With a 1-year increase in age, the nogo-N200 latency at Fz and Cz decreased by 6.08 ms and 4.88 ms, respectively; this result was statistically significant in multivariable linear regression adjusted by sex and dominant hand.Conclusion Our findings revealed age-related changes in nogo-N200 latency at the Fz and Cz electrodes in individuals with ADHD. Future studies should perform comparisons with healthy controls to determine whether auditory nogo-N200 can be used to evaluate the developmental level in individuals with ADHD.

scholarly journals A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder

2021 ◽  
Author(s):  
Stephen V. Faraone ◽  
Roberto Gomeni ◽  
Joseph T. Hull ◽  
Gregory D. Busse ◽  
Zare Melyan ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Children And Adolescents ◽  
Attention Deficit ◽  
Extended Release ◽  
Rating Scale ◽  
Adhd Symptoms ◽  
School Problems ◽  
Post Hoc Analysis ◽  
Hyperactivity Disorder ◽  
Post Hoc

AbstractImprovement in attention-deficit/hyperactivity disorder (ADHD) symptoms vs. placebo was reported in a series of pediatric clinical trials of viloxazine extended-release capsules (viloxazine ER; Qelbree™). This post hoc analysis of those studies evaluated the effect of viloxazine ER on learning and school problems (LSPs). We used data from four Phase 3 placebo-controlled trials of 100–600 mg/day viloxazine ER (N = 1354; 6–17 years of age). LSPs were evaluated using the School domain of the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P-S) and the Learning Problems content scale of the Conners 3rd Edition-Parent Short Form (C3PS-LP) at baseline and end of study (≥ Week 6). ADHD symptoms were assessed weekly using the ADHD Rating Scale 5th Edition. The analyses were performed using the general linear mixed model with participant as a random effect. The responder analyses were performed using the Chi-square test. Viloxazine ER demonstrated significantly greater improvements in WFIRS-P-S (p < 0.0001) and C3PS-LP (p = 0.0113) scores vs. placebo. The response rate for the WFIRS-P-S was significantly greater for viloxazine ER vs. placebo (p = 0.001), and the number needed to treat (NNT) was 10.3 (effect size 0.7). Conversely, response rates for C3PS-LP did not differ between groups (p = 0.9069). In addition to ADHD symptoms improvement demonstrated in previous studies, viloxazine ER significantly reduced LSPs in pediatric subjects with ADHD. The responder analyses and NNT estimates indicate that a substantial number of children and adolescents with ADHD treated with viloxazine ER improved in clinically assessed LSPs.

scholarly journals A Comparison of Methylphenidate (MPH) and Combined Methylphenidate with Crocus sativus (Saffron) in the Treatment of Children and Adolescents with ADHD: A Randomized, Double-Blind, Parallel-Group, Clinical Trial

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Mojtaba Khaksarian ◽  
Saba Hasanvandi ◽  
Iman Mirr ◽  
Hassan Jafari ◽  
Saeed Kordian ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Children And Adolescents ◽  
Attention Deficit ◽  
Repeated Measures ◽  
Rating Scale ◽  
Combined Treatment ◽  
Crocus Sativus ◽  
Average Score ◽  
Double Blind ◽  
Hyperactivity Disorder

Background: Attention-deficit/hyperactivity disorder (ADHD) is characterized by behavioral and neurodevelopmental problems. It is estimated that 3 - 7% of children and adolescents suffer from this problem. Apart from synthetic drugs, other effective types of medication like herbal medicines are of great importance. Objectives: This study aimed to evaluate the effectiveness of methylphenidate (MPH) and its combination with Crocus sativus (saffron) in the treatment of children suffering from ADHD. Methods: The sample included 70 children aged between 6 and 16 years who had been diagnosed with ADHD. The patients were randomly assigned into two equal groups (n = 35 in each group). While both groups received 20 or 30 mg/d of MPH (20 and 30 mg/d for < 30 and > 30, respectively), one of them also received 20 or 30 mg/d of saffron in a capsule based on BMI (20 and 30 mg/d for < 30 and > 30, respectively). To collect data, parents and teachers completed Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV). Also, for analyzing the data, the repeated measures analysis of variance (RMANOVA) was used. Results: The results of general linear model (GLM) repeated measures indicated that in both groups, the patients had less symptoms after eight weeks of treatment. However, after four weeks, the average score assigned by the parents and teachers in the MPH with saffron group was lower than the average total score in the MPH group (P < 0.05). Conclusions: Using MPH combined with saffron proved to be more effective in the treatment of patients suffering from ADHD compared to separate treatments. It seems that the duration of therapy can be reduced and the effectiveness be improved by prescribing proposed combined treatment.

Sign in / Sign up

Export Citation Format

Share Document